Routine

Barrett's oesophagus — surveillance & management

Barrett's · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Columnar (intestinal) metaplasia of the distal oesophagus from chronic reflux, a premalignant precursor to oesophageal adenocarcinoma. Risk is stratified by segment length and dysplasia grade, which set surveillance intervals and the threshold for endoscopic eradication.

Red flags

  • New dysphagia or odynophagia
  • Weight loss or iron-deficiency anaemia
  • Visible nodule, ulcer or stricture within the segment
  • Rapid progression of dysplasia grade

Assessment

Differential diagnosis

  • Gastro-oesophageal junction irregularity (non-dysplastic)
  • Reflux oesophagitis with pseudo-columnar change
  • Eosinophilic oesophagitis
  • Oesophageal adenocarcinoma
  • Hiatus hernia with columnar-lined lower oesophagus

Investigations

  • High-resolution white-light + narrow-band imaging endoscopy
  • Seattle protocol biopsies (4-quadrant every 2 cm) plus targeted biopsies of visible lesions
  • Prague C&M classification of segment length
  • Dysplasia grading by two GI pathologists (confirm any dysplasia)
  • FBC/ferritin if bleeding or anaemia

Management

  • Confirm true Barrett's: ≥1 cm columnar segment above GOJ with intestinal metaplasia on biopsy
  • Document Prague C&M length and photograph/map any visible lesions
  • Take Seattle-protocol biopsies plus targeted sampling of mucosal irregularities
  • Optimise reflux control with once-daily PPI (symptom and mucosal healing, not chemoprevention proven)
  • Risk-stratify: non-dysplastic short segment (<3 cm) vs long segment vs dysplasia
  • Non-dysplastic <3 cm with intestinal metaplasia: surveillance every 3–5 years
  • Non-dysplastic ≥3 cm: surveillance every 2–3 years
  • Indefinite for dysplasia: optimise PPI, repeat endoscopy in 6 months
  • Confirmed low-grade dysplasia: refer for endoscopic eradication (radiofrequency ablation) or 6-monthly surveillance if declined
  • High-grade dysplasia or intramucosal cancer: endoscopic resection of visible lesions + ablation at expert centre
  • Give weight-loss, smoking cessation and reflux lifestyle advice
  • Enter into a tracked surveillance register with clear recall

Drugs & doses

Omeprazole 20–40 mg PO once daily
Esomeprazole 40 mg PO once daily (alternative)
Lansoprazole 30 mg PO once daily (alternative)

Disposition

Outpatient GI surveillance clinic with structured recall; refer dysplasia/early cancer to a Barrett's/upper-GI MDT at an expert endotherapy centre.

Complications & pitfalls

  • Oesophageal adenocarcinoma
  • Post-ablation stricture
  • Bleeding or perforation after endoscopic resection
  • Buried/recurrent intestinal metaplasia

Exam pearls

  • Intestinal metaplasia on biopsy is required for the diagnosis in most guidelines — not columnar appearance alone
  • Any dysplasia must be confirmed by a second expert GI pathologist before acting
  • Endoscopic eradication is now standard for confirmed low-grade dysplasia, not just high-grade
  • Do not biopsy during active oesophagitis — treat with PPI and re-scope

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.